S
Shenping Liu
Researcher at Pfizer
Publications - 43
Citations - 1866
Shenping Liu is an academic researcher from Pfizer. The author has contributed to research in topics: Glucokinase & Binding site. The author has an hindex of 22, co-authored 41 publications receiving 1598 citations.
Papers
More filters
Journal ArticleDOI
Insights into Mechanism of Glucokinase Activation: OBSERVATION OF MULTIPLE DISTINCT PROTEIN CONFORMATIONS.
Shenping Liu,Mark Ammirati,Xi Song,John D. Knafels,Jeffrey Zhang,Samantha Elizabeth Greasley,Jeffrey A. Pfefferkorn,Xiayang Qiu +7 more
TL;DR: The structure of the catalytic complex of GK has been determined, and multiple conformations have been directly observed in solution, and a modified mnemonic model is proposed to explain cooperativity in GK.
Journal ArticleDOI
Transcriptional Profiling of a Selective CREB Binding Protein Bromodomain Inhibitor Highlights Therapeutic Opportunities.
Eugene Lvovich Piatnitski Chekler,Jessica A. Pellegrino,Thomas A. Lanz,R. Aldrin Denny,Andrew C. Flick,Jotham Wadsworth Coe,Jonathan Langille,Arindrajit Basak,Shenping Liu,Ingrid A. Stock,Parag Sahasrabudhe,Paul D. Bonin,Kevin Lee,Mathew T. Pletcher,Lyn H. Jones +14 more
TL;DR: The structure-based design of a highly selective inhibitor of the CREB binding protein (CBP) bromodomain is described and its use in cell-based transcriptional profiling experiments is described, suggesting a potential therapeutic opportunity for CBP inhibitors in the treatment of neurological disorders.
Journal ArticleDOI
Inhibiting complex IL-17A and IL-17RA interactions with a linear peptide
Shenping Liu,Joel Desharnais,Parag Sahasrabudhe,Ping Jin,Wei Li,Bryan Oates,Suman Shanker,Mary Ellen Banker,Boris A. Chrunyk,Xi Song,Xidong Feng,Matt Griffor,Judith Jimenez,Gang Chen,David Tumelty,Abhijit Bhat,Curt Bradshaw,Gary Woodnutt,Rodney W. Lappe,Atli Thorarensen,Xiayang Qiu,Jane M. Withka,Wood Lauren Diane +22 more
TL;DR: A high affinity IL-17A peptide antagonist (HAP) of 15 residues was identified through phage-display screening followed by saturation mutagenesis optimization and amino acid substitutions and suggests opportunities for developing peptide antagonists against this challenging target.
Journal ArticleDOI
Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists.
Shenping Liu,Leslie Anthony Dakin,Li Xing,Jane M. Withka,Parag Sahasrabudhe,Wei Li,Mary Ellen Banker,Paul Balbo,Suman Shanker,Boris A. Chrunyk,Zuojun Guo,Jinshan M. Chen,Jennifer A. Young,Guoyun Bai,Jeremy T. Starr,Stephen W. Wright,Joerg Bussenius,Sheng Tan,Ariamala Gopalsamy,Bruce Allen Lefker,Fabien Vincent,Lyn H. Jones,Hua Xu,Lise R. Hoth,Kieran F. Geoghegan,Xiayang Qiu,Mark E. Bunnage,Atli Thorarensen +27 more
TL;DR: Investigation of a series of linear peptide ligands to IL-17A and characterization of their binding site has enabled the design of novel macrocyclic ligands that are themselves potent IL- 17A antagonists.
Journal ArticleDOI
Lysosomal integral membrane protein-2 as a phospholipid receptor revealed by biophysical and cellular studies
Karen S. Conrad,Ting Wen Cheng,Daniel Ysselstein,Saskia Heybrock,Lise R. Hoth,Boris A. Chrunyk,Christopher W. am Ende,Dimitri Krainc,Michael Schwake,Paul Saftig,Shenping Liu,Xiayang Qiu,Michael D. Ehlers,Michael D. Ehlers +13 more
TL;DR: The authors show that LIMP-2 is also a phospholipid receptor and present the lipid-bound structure of the LIMp-2 luminal domain dimer and discuss its lipid trafficking mechanism.